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25 mice/group; P < 0.001). Speciﬁc GrB inhibition by iNKT
pre-treatment with the non-competitive inhibitor Z-AAD-
CMK abrogated CD2/CD3/CD28 augmented iNKT cytotox-
icity, both in vitro and in vivo. Using permutations of CD2,
CD3, and CD28 stimulation combined with speciﬁc inhibitors
of the PI3K-AKT-mTORC pathway, we deﬁned that CD3/
CD28-co-stimulated, PI3K-downstream, mTORC2-driven
AKT activation directly up-regulates GrB protein expression
and augments GrB-dependent cytotoxicity in expanded hu-
man iNKT cells. Notably, CD2/CD3/CD28-induced augmented
iNKT killing was not inhibited by cyclosporin A, rapamycin,
or tacrolimus. These data demonstrate the novel potential for
augmentation of cytokine secretion and cytotoxicity in hu-
man iNKT cells through AKT signaling independent of
mTORC1 or NF-AT, deﬁning a key pathway for control of iNKT
effector functions with broad implications for immuno-
therapy, vaccine augmentation, and anti-infective therapies.
As our studies utilized random donor human iNKT cells
expanded using a clinically applicable protocol, these data
are directly relevant to therapeutic human iNKT cell
manipulation to separate GVHD and GVT in the peri-
transplant or non-transplant setting of human iNKT
immunotherapy.503
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Allogeneic hematopoietic cell transplantation (allo-HCT) for
hemoglobinopathies is restricted by limited matched donors
and by graft rejection and graft-versus-host disease (GVHD)
after alternative donor HCT. Based upon our clinical data in
aplastic anemia (Pillai et al, ASBMT 2011), we pre-clinically
assessed non-myeloablative Total Lymphoid Irradiation (TLI)
+ Anti-Thymocyte Serum (ATS) +/- cyclophosphamide (CTX)
vs. total body irradiation (TBI)/ATS +/- CTX in an MHC-mis-
matched BALB/c (H-2d) into HW-80 (H-2b) b-thalassemia
(HW-80 b-thal+/-) model.
Methods: Wild-type (WT) and b-thal+/- HW-80 mice
received TLI (240 cGy x 10) + ATS (TLI/ATS, n ¼ 10), +/- CTX
(200 mg/kg) (TLI/ATS/CTX, n ¼ 15), ATS/CTX alone (n ¼ 10),
or ATS/CTX with 1200 cGy, 600 cGy, or 300 cGy TBI (1200 T/
A/C, 600 T/A/C, 300 T/A/C; n ¼ 10 each), and 50 x 106 bone
marrow + 60 x 106 splenocytes (BMT) from WT BALB/c do-
nors. Survival, weekly weight, day 28 and day 100 tri-lineage
engraftment and CBC, and histopathologic GVHD were
assessed.
Results: WT HW-80 recipients of either TLI/ATS or TLI/ATS/
CTX engrafted through day 100; HW-80 b-thal+/- mice had >
40% graft rejection after TLI/ATS + BMT, but 100% graft
retention after TLI/ATS/CTX + BMT, indicating a disease-
associated engraftment barrier overcome by addition of CTX
to TLI/ATS. All engrafting b-thal+/- mice showed stable mixed
hematopoietic chimerism and day 100 hematocrit (Hct)
correction (P ¼ 0.01 vs untreated b-thal+/-). However, TLI/
ATS/CTX recipients had no GVHD, whereas engrafting TLI/
ATS mice developed lethal GVHD by day 100 [cumulative
scores: TLI/ATS/CTX: 0.3 +/- 0.2; TLI/ATS: 6.8 +/- 0.9; P <
0.01]. 100% of 1200 T/A/C, 60% of 600 T/A/C, and 40% of 300 T/A/C mice engrafted. In all T/A/C groups, > 80% engrafters had
lethal GVHD, whereas > 70% of 100-day survivors showed
non-engraftment. We delineated that recipient regulatory
MDSC induce tolerance via MHC-independent in vivo
expansion of donor Foxp3+ nTreg after TLI/ATS + BMT (van
der Merwe et al, J Immunol 2013). We found signiﬁcant (P <
0.001) increase in recipient CD11b+Gr-1(G)hi MDSC in TLI/
ATS/CTX- versus TLI/ATS-conditioned b-thal+/- mice, with
increased number (P < 0.01) and proliferation (P < 0.05) of
donor Foxp3+ nTreg and decreased CD8+ T cell number and
proliferation (P < 0.01) in spleens at day 6. In adoptive
transfers, TLI/ATS/CTX-derived recipient CD11b+Gr-1Ghi
MDSC regulated otherwise lethal GVHD through day 100
post-BMT in 1200 cGy TBI-conditioned WT B6 recipients of
WT BALB/c BMT. Our data indicate that TLI/ATS/CTX facili-
tates robust recipient <–> donor tolerance, provide pre-
clinical support for application of TLI/ATS/CTX prior to
(potentially MHC-mismatched/haploidentical) allo-HCT for
hemoglobinopathies, and give the ﬁrst direct evidence for an
innate immune mechanism of alkylator-associated trans-
plantation tolerance, which we propose to validate in the
context of a clinical trial.504
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Introduction: While DCBT has been associated with high
PFS in both children & adults, rates of grade II-IV aGVHD are
signiﬁcant in patients transplanted with calcineurin inhibi-
tor/ mycophenolate mofetil (CNI/MMF) immunosuppression
(IS) without anti-thymocyte globulin. However, GVHD
biology in DCBT recipients appears distinct from that of adult
donor allografts with a high incidence of corticosteroid
responsiveness & low rates of chronic GVHD. Consequently,
the impact of aGVHD upon long-term PFS in DCBT may be
different to that of adult donor allografts & is not established.
Methods: We analyzed the time to systemic (sys.) IS cessa-
tion, transplant-related mortality (TRM), relapse, & PFS in a
day 100 landmark analysis of DCBT recipients transplanted
for hematologic malignancies who were engrafted &
progression-free according to the incidence & severity of
their aGVHD by day 100.
Results: 129 day 100 progression-free DCBT survivors (me-
dian age 36 years, range 0.9-70) were evaluated. Of this
cohort, 80 (62%) had grade II-IV aGVHD (55 grade II, 21 grade
III, & 4 grade IV disease), & all 129 patients were on sys.IS at
day 100.With a median follow-up of 4.8 years (range 1.2-9.0)
in this cohort, the cumulative incidence of achieving sus-
tained sys.IS cessation was 33% (95%CI: 25-42) at 1-year, 55%
(95%CI: 45-63) at 2-years, & 61% (95%CI: 51-69) at 3-years
Figure 1.
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5.6) post-DCBT. Of 103 progression-free survivors at 1-year,
26 (25%) were on high, 26 (25%) on intermediate, 18 (17%) on
low dose sys.IS, & 33 (32%) were on no sys.IS. The number of
patients on any sys.IS decreased to 30% in evaluable pro-
gression-free survivors at 2-years, & 18% at 3-years. A total of
84/129 (65%) patients survive progression-free to date from
the day 100 landmark with 24 having died of TRM (17 GVHD-
related), 1 from relapsed sarcoma, & 20 have relapsed/pro-
gressed. The 3-year incidence of TRM according tomaximum
day 100 aGVHD grade was 11% (95%CI: 4-22) in grade 0-I &
24% (95%CI: 15-34) in grade II-IV patients, p ¼ 0.14. The 3-
year incidence of relapse was 20% (95%CI: 10-34) in grade 0-I
& 11% (95%CI: 6-20) in grade II-IV patients, p ¼ 0.54. Overall,
there was no difference in the 3-year PFS of 69% (95%CI: 56-
84) in those whose day 100 aGVHD grade was 0-I when
compared to the 65% (95%CI: 55-76) PFS in patients whose
aGVHD grade was II-IV (Figure).
Conclusions: In patients alive at day 100, most will achieve
sustained cessation of sys.IS despite initial aGVHD.Moreover,
while the contribution of aGVHD to TRM is signiﬁcant, there
was no statistical difference in overall TRM in the GVHD
groups. Finally, grade 0-I versus II-IV aGVHD had no impact
on long-term PFS. Thus, despite an approximate 50% inci-
dence of grade II-IV aGVHD in DCBT recipients at our center
(Ponce et al, BBMT 2013), long-term PFS is not impacted in
day 100 survivors & the majority of patients are off IS after 2
years post-allograft.Figure 1. FEV1 and prednisone dose for Subject 8A and 14A505
Inhaled Cyclosporine Solution for the Treatment of
Bronchiolitis Obliterans Following Hematopoietic Stem
Cell Transplantation (HSCT) or Lung Transplantation
Enkhtsetseg Purev 1, Nicole Gormley 1, Catalina Ramos 1,
Robert Reger 1, Xin Tian 2, Elena Cho 1, Debra Reda 3,
Clara Chen 4, Anthony F. Suffredini 3, Richard W. Childs 1.
1Hematology Branch, National Heart, Lung, and Blood
Institute, Bethesda, MD; 2Ofﬁce of Biostatistics Research,
National Heart, Lung, and Blood Institute, NIH, Bethesda, MD;
3 Critical Care Medicine Department, National Institutes of
Health, Bethesda, MD; 4Department of Radiology and Imaging
Sciences, National Institutes of Health, Bethesda, MDBronchiolitis Obliterans Syndrome (BOS) is a late pulmonary
complication of both lung and HSCT resulting in obstructive
lung disease. For the latter, BOS is thought to be a manifes-
tation of chronic graft versus host disease (cGVHD). The
mainstay of therapy is systemic immunosuppression, which
increases the risk of infection and reduces graft versus tumor
effects. We investigated whether targeted, local delivery of
inhaled cyclosporine could improve or stabilize lung func-
tion in BOS patients.
HSCT and lung transplant recipients with BOS were
eligible if they met the following inclusion criteria:
FEV1<75% predicted, FEV1 decline >10% compared to pre-
transplant FEV1, no evidence of pulmonary infection as
causative etiology, and one of the following: FEV1/FVC ratio
<70%, air-trapping seen on CT scan or RV 120%, or evidence
of cGVHD affecting at least one other organ system. Subjects
received cyclosporine inhalation solution (CIS) 150 mg via
nebulizer 3 times weekly for 6 weeks before dose escalation
to 300mg three times weekly. Pharmacokinetic and lung
deposition studies were performed. The primary endpoint
was change in FEV1 at study completion (average of week 18
and 19) compared to study baseline.
16 subjects have been enrolled (median age: 45 years;
range: 14-73); 14 had HSCT-associated BOS, and 2 had lung-
transplant-associated BOS. The median time from BOS diag-
nosis to study enrollment was 9 months (range: 2-37). The
median FEV1 at study entry was 1.1 liters (range: 0.5-2.11).
One patient suffered a severe adverse event with CIS (cough,
bronchospasm, and dyspnea requiring hospitalization).
Adverse events associated with CIS occurred in 11/12 patients
and included grade 2 (range 1-3) cough, bronchospasm, and
dyspnea that occurred primarily during inhalation.
Of the 12 evaluable subjects, 4 subjects went off-study (pa-
tient choice) prior to completion of the 18 weeks, and were
considered non-responders. Responses were observed in 5/10
subjects (50%) with BOS following HSCT. Among responding
patients who had an improvement in their FEV1, 3 were also
able to decrease their systemic steroid dose (Figure 1). The
median peak systemic absorption of cyclosporine was 99
